• PRESAGE BIOSCIENCES

    A Pioneer In Translational Oncology

    We bring innovation to cancer drug development. Our platform is uniquely capable of unraveling complexities of how patient tumors respond to drug exposure.
  • A bridge between preclinical insights and patient care

    The Forefront of Translational Medicine

    Using Presage's patented CIVO (Comparative In Vivo Oncology) platform, tumor microenvironment response to multiple investigational treatments, alone or in combination, can be observed where it matters most—in a patient's tumor.

  • Presage’s proprietary drug development platform

    The CIVO® Platform

    The CIVO (Comparative In Vivo Oncology) platform is an innovative translational oncology offering that encompasses a novel intratumoral delivery technology, a sophisticated operation, and highly detailed analysis. The platform is uniquely capable of providing comprehensive insights into the tumor microenvironment.

    PRESAGE BIOSCIENCES IS BREAKING GROUND IN TRANSLATIONAL ONCOLOGY RESEARCH. WE ARE UNIQUELY POISED TO REPORT, IN DETAIL, WHAT HAPPENS WHEN THE TUMOR MICROENVIRONMENT IS EXPOSED TO DRUGS.

    Revolutionizing oncology drug development
    Presage is at the forefront of changing how novel cancer therapies are developed and promising drug combinations are identified. With Phase 0 microdose trials, evaluation of tumor-based drug activity is now possible earlier than ever before.
    See how CIVO works
    A bridge between early preclinical
    experimentation and clinical investigation
    Using Presage's patented CIVO (Comparative In Vivo Oncology) platform, tumor microenvironment response to multiple investigational treatments, alone or in combination, can be observed where it matters most—in a patient's tumor.
    Discover the benefit of phase 0 microdosing
    Presage CIVO
    An innovative translational oncology offering aligned with crl’s mission
    See how CIVO works
    Previous
    Next
    PRESAGE BIOSCIENCES IS BREAKING GROUND IN TRANSLATIONAL ONCOLOGY RESEARCH. WE ARE UNIQUELY POISED TO REPORT, IN DETAIL, WHAT HAPPENS WHEN THE TUMOR MICROENVIRONMENT IS EXPOSED TO DRUGS.
    PRESAGE IS AN EMERGING LEADER IN TRANSLATIONAL ONCOLOGY AND IS THE ONLY COMPANY IN THE WORLD THAT ENABLES SAFE EVALUATION OF MULTIPLE DRUG CANDIDATES AND COMBINATIONS SIMULTANEOUSLY IN CANCER PATIENTS.
    WE UNRAVEL THE COMPEXITY OF DRUG-TUMOR INTERACTIONS. WE ACCURATELY TRACK POSITIONS OF DRUG EXPOSURE AND EXAMINE RESPONSES THROUGH DETAILED CELL AND MOLECULAR PROFILING.
    [Downloader.la]-620b7b55ade30

    About Presage

    Presage’s patented CIVO® (Comparative In Vivo Oncology) technology delivers microdoses of multiple drugs to different regions of a tumor, while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring tumor has the potential to provide a more detailed understanding of tumor biology, directly encompassing a patient’s own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.

    Cancer Drug Development Needs More Predictive Platforms For Testing Candidate Agents

    One important bottleneck in oncology drug development is the inability of preclinical models to accurately model the tumor microenvironment in human patients.

    Preclinical CIVO Offerings Available

    CIVO highlights immune effects in syngeneic models

    Well-versed w/ over
    Tumor Models

    Approximately 1000 drugs and drug combinations evaluated

    Ability to run preclinical studies in-house

    Expert tumor modeling, histology, and image analysis staff

    Amenable to all injectable drug modalities

    Dedicated project management support

    Well-versed w/ over
    Tumor Models

    Expert tumor modeling, histology and image analysis staff

    Approximately 1000 drugs and drug combinations evaluated

    Amenable to all injectable drug modalities

    Ability to run preclinical studies in-house

    Dedicated project management support

    Preclinical CIVO Offerings Available

    CIVO highlights immune effects in syngeneic models

    Team Members

    Rich
    Richard Klinghoffer
    Ph.D
    SVP, Device R&D
    John Streeter
    SVP, Device R&D
    Brad
    Brad Margus
    Board Member
    Jong
    Jong Chang
    MBA credentials for uniformity
    Michele
    Michele Cleary
    Ph.D.
    Sam
    Sam Blackman
    M.D., Ph.D.

    Fundamentally changing cancer
    drug development

    In a few simple steps, this patented process can simultaneously evaluate multiple drugs or
    drug combinations using 100+ assays for tumor microenvironment responses.

    01
    CIVO injects drug microdoses directly into a patient's tumor. The device delivers trackable drug "columns."
    02
    Drugs interact with the tumor while still within the patient. Then the tumor is surgically removed.
    03
    The tumor tissue is processed by sectioning crosswise to the drug columns. Four-micron sections are then cut and placed onto slides for staining.
    04
    Tumor slices are assessed for response around each injection site using CIVOanalyzer
    05
    CIVOanalyzer delivers automated response quantification via radial distance calculations, effectively comparing responses between drugs and drug combinations.
    06
    Spatial biology or how the insights can be applied?

    CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL
    PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY

    Presage A Translational
    Oncology Company

    Nine issued US patents
    “A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is in vivo, and wherein the solid tissue is a tumor.”

    Presage's Partners

    A pioneering solution, turnkey operation

    A pioneering solution, turnkey operation, revenue-generating partnerships2016 - 2021